Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | PTGIR | P43119 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | NMBR | P28336 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16219074 | 0.90 | ALOX5 (0.44) | DPP4PREPFAPALOX5NMBR | |
| SCHEMBL14540448 | 0.87 | KDM4E (0.44) | DPP4PREPFAPCNR2KDM4E | |
| SCHEMBL19652262 | 0.82 | SMN1; SMN2 (0.42) | DPP4PREPFAPKDM4EPKM | |
| SCHEMBL22856554 | 0.81 | PIK3CD (0.41) | DPP4PREPFAPKDM4EALDH1A1 | |
| SCHEMBL26145707 | 0.80 | KDM4E (0.38) | DPP4PREPFAPKDM4E | |
| SCHEMBL22906377 | 0.80 | EPHX1 (0.39) | DPP4PREPFAP | |
| SCHEMBL25895277 | 0.80 | DPP4 (0.38) | DPP4PREPFAPKDM4E | |
| SCHEMBL19652204 | 0.80 | DPP4 (0.41) | DPP4PREPFAP | |
| SCHEMBL16160071 | 0.79 | ALOX5 (0.33) | DPP4PREPFAPALOX5ARG1 | |
| SCHEMBL24673322 | 0.79 | DPP4 (0.37) | DPP4PREPFAPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4183783-A1 | IMMUNOMODULATOR | Hitgen Inc. (CN) | 2023-05-24 | — | — | EP | disclosed |
| US-20230118497-A1 | PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20150299178-A1 | Thiazole Derivatives as Alpha 7 NACHR Modulators | LUPIN LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| WO-2005021584-A2 | NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230118497-A1 | PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | DPP4 535/4885PREP 234/4885FAP 340/4885 |
| US-20150299178-A1 | Thiazole Derivatives as Alpha 7 NACHR Modulators | CHRNA7, CHRM1, CHRM2 | DPP4 1786/4885PREP 4308/4885FAP 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.